Effects of cyclooxygenase inhibition on the gastrointestinal tract

Experimental and Toxicologic Pathology

Volumn 58, Issue 2-3, 2006, Pages 163-173

  Radi, Zaher A ^a   Khan, Nasir K ^a  

^a PFIZER INC   (United States)

Author keywords

Coxibs; Cyclooxygenase; Gastrointestinal tract; NSAIDs

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; 5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; 6 (2,4 DIFLUOROPHENYLTHIO) 5 METHANESULFONAMIDO 1 INDANONE; ACETYLSALICYLIC ACID; CARPROFEN; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; ETODOLAC; FENBUFEN; FLUNIXIN MEGLUMINE; IBUPROFEN; INDOMETACIN; KETOPROFEN; LORNOXICAM; LOXOPROFEN; MELOXICAM; MISOPROSTOL; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PHENYLBUTAZONE; PIROXICAM; PLACEBO; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; TENOXICAM; UNINDEXED DRUG;

ABDOMINAL PAIN; ADENOMATOUS POLYP; ANEMIA; ANOREXIA; APPETITE DISORDER; ARTICLE; ATROPHY; BIOLOGICAL MODEL; BLOOD DYSCRASIA; CECUM DISEASE; CLINICAL TRIAL; COLITIS; COLON ULCER; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DISEASE PREDISPOSITION; DOG; DOMESTIC ANIMAL; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG SAFETY; DUODENUM ULCER; DYSPEPSIA; ENTERIC COATED TABLET; ENZYME INHIBITION; ESOPHAGITIS; ESOPHAGUS STRICTURE; EXPERIMENTAL ANIMAL; GASTRITIS; GASTRODUODENAL ULCER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL IRRITATION; GASTROINTESTINAL TOXICITY; GASTROINTESTINAL TRACT; GOAT; HEMATOCHEZIA; HORSE; HUMAN; HYPOPROTEINEMIA; INFLAMMATION; INTESTINE PERFORATION; INTESTINE ULCER; MAXIMUM PERMISSIBLE DOSE; MELENA; MICROANGIOPATHY; MONKEY; NONHUMAN; PATHOPHYSIOLOGY; PERITONITIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SHOCK; SKIN INFLAMMATION; SPECIES COMPARISON; SPECIES DIFFERENCE; STOMACH EROSION; STOMACH HEMORRHAGE; STOMACH INJURY; STOMACH LESION; STOMACH PERFORATION; STOMACH ULCER; SWINE; TISSUE DISTRIBUTION; TRANSITIONAL CELL CARCINOMA; ULCERATIVE COLITIS; VETERINARY MEDICINE; VOMITING; WEIGHT REDUCTION;

ANIMALIA;

EID: 33750321297     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.etp.2006.06.004     Document Type: Article

References (114)

1. Adams S.S., Bough R.G., Cliffe E.E., Lessel B., et al. Absorption, distribution and toxicity of ibuprofen. Toxicol Appl Pharmacol 15 (1969) 310-330
2. Altinkaynak K., Suleyman H., and Akcay F. Effect of nimesulide, rofecoxib and celecoxib on gastric tissue glutathione level in rats with indomethacin-induced gastric ulcerations. Pol J Pharmacol 55 (2003) 645-648
3. Anthony A., Dhillon A.P., Sim R., et al. Ulceration, fibrosis and diaphragm-like lesions in the caecum of rats treated with indomethacin. Aliment Pharmacol Ther 8 (1994) 417-424
4. Arai I., Hamasaka Y., Futaki N., et al. Effect of NS-398, a new nonsteroidal anti-inflammatory agent, on gastric ulceration and acid secretion in rats. Res Commun Chem Pathol Pharmacol 81 (1993) 259-270
5. Atzpodien E., Mehdi N., Clarke D., et al. Subacute and chronic oral toxicity of lornoxicam in cynomolgus monkeys. Food Chem Toxicol 35 (1997) 465-474
6. Bjorkman D.J. Nonsteroidal anti-inflammatory drug-induced gastrointestinal injury. Am J Med 101 (1996) 25S-32S
7. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343 (2000) 1520-1528
8. Brodie D.A., Cook P.G., Bauer B.J., et al. Indomethacin-induced intestinal lesions in the rat. Toxicol Appl Pharmacol 17 (1970) 615-624
9. Budsberg S.C., Johnston S.A., Schwarz P.D., et al. Efficacy of etodolac for the treatment of osteoarthritis of the hip joints in dogs. J Am Vet Med Assoc 214 (1999) 206-210
10. Campbell N.B., and Blikslager A.T. The role of cyclooxygenase inhibitors in repair of ischaemic-injured jejunal mucosa in the horse. Equine Vet J 32 (2000) 59-64
11. Carrick J.B., Papich M.G., Middleton D.M., et al. Clinical and pathological effects of flunixin meglumine administration to neonatal foals. Can J Vet Res 53 (1989) 195-201
12. Collins L.G., and Tyler D.E. Experimentally induced phenylbutazone toxicosis in ponies: description of the syndrome and its prevention with synthetic prostaglandin E2. Am J Vet Res 46 (1985) 1605-1615
13. Conlon P.D. Nonsteroidal drugs used in the treatment of inflammation. Vet Clin North Am Small Anim Pract 18 (1988) 1115-1131
14. Coppelli G., Guaita E., Spaggiari S., et al. Gastric effects of the selective cyclooxygenase-2 inhibitor, celecoxib, in the rat. Dig Liver Dis 36 (2004) 265-270
15. Cosenza S.F. Drug-induced gastroduodenal ulceration in dogs. Modern Vet Pract 65 (1984) 923-925
16. Court M.H., and Greenblatt D.J. Molecular basis for deficient acetaminophen glucuronidation in cats. An interspecies comparison of enzyme kinetics in liver microsomes. Biochem Pharmacol 53 (1997) 1041-1047
17. Crofford L.J., Oates J.C., Mccune W.J., Gupta S., et al. Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases. Arthritis Rheum 43 (2000) 1891-1896
18. Cuzzocrea S., Mazzon E., Serraino I., et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor reduces the severity of experimental colitis induced by dinitrobenzene sulfonic acid in rats. Eur J Pharmacol 431 (2001) 91-102
19. Daehler M.H. Transmural pyloric perforation associated with naproxen administration in a dog. J Am Vet Med Assoc 189 (1986) 694-695
20. Dannenberg A.J., Altorki N.K., Boyle J.O., et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2 (2001) 544-551
21. Duggan D.E., Hooke K.F., Noll R.M., et al. Enterohepatic circulation of indomethacin and its role in intestinal irritation. Biochem Pharmacol 24 (1975) 1749-1754
22. Eckmann L., Stenson W.F., Savidge T.C., et al. Role of intestinal epithelial cells in the host secretory response to infection by invasive bacteria. Bacterial entry induces epithelial prostaglandin h synthase-2 expression and prostaglandin E2 and F2alpha production. J Clin Invest 100 (1997) 296-309
23. Eling T.E., Thompson D.C., Foureman G.L., et al. Prostaglandin H synthase and xenobiotic oxidation. Annu Rev Pharmacol Toxicol 30 (1990) 1-45
24. Elliott S.L., Ferris R.J., Giraud A.S., et al. Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH. Clin Exp Pharmacol Physiol 23 (1996) 432-434
25. Elliott G.A., Purmalis A., Vandermeer D.A., et al. The propionic acids. Gastrointestinal toxicity in various species. Toxicol Pathol 16 (1988) 245-250
26. Ewing G.O. Indomethacin-associated gastrointestinal hemorrhage in a dog. J Am Vet Med Assoc 161 (1972) 1665-1668
27. Eyre P., Boulard C., and Deline T. Local and systemic reactions in cattle to Hypoderma lineatum larval toxin: protection by phenylbutazone. Am J Vet Res 42 (1981) 25-28
28. Fang W.F., Broughton A., and Jacobson E.D. Indomethacin-induced intestinal inflammation. Am J Dig Dis 22 (1977) 749-760
29. Forsyth S.F., Guilford W.G., Haslett S.J., et al. Endoscopy of the gastroduodenal mucosa after carprofen, meloxicam and ketoprofen administration in dogs. J Small Anim Pract 39 (1998) 421-424
30. Fox S.M., and Johnston S.A. Use of carprofen for the treatment of pain and inflammation in dogs. J Am Vet Med Assoc 210 (1997) 1493-1498
31. Futaki N., Yoshikawa K., Hamasaka Y., et al. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol 24 (1993) 105-110
32. Godshalk C.P., Roush J.K., Fingland R.B., et al. Gastric perforation associated with administration of ibuprofen in a dog. J Am Vet Med Assoc 201 (1992) 1734-1736
33. Goldstein J.L., Correa P., Zhao W.W., et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 96 (2001) 1019-1027
34. Goldstein J.L., Binofsky A., Eisen G., et al. Small bowel mucosal lesions and drug tolerability with naproxen plus omepraxole, celecoxib, and placebo in healthy subjects using capsule endoscopy: results from a double-blind randomized, controlled trial. Arthritis Rheum 48 (2003) 3662
35. Gullikson G.W., Anglin C.P., Kessler L.K., et al. Misoprostol attenuates aspirin-induced changes in potential difference and associated damage in canine gastric mucosa. Clin Invest Med 10 (1987) 145-151
36. Hallesy DW, Shott LD, Hill R. Comparative toxicology of naproxen. Scand J Rheumatol 1973; Suppl 2: 220-8.
37. Hawkey C.J., and Skelly M.M. Gastrointestinal safety of selective COX-2 inhibitors. Curr Pharm Des 8 (2002) 1077-1089
38. Hawkey C., Laine L., Simon T., et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum 43 (2000) 370-377
39. Jackson L.M., Wu K.C., Mahida Y.R., et al. Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa. Gut 47 (2000) 762-770
40. Johnston S.A., and Budsberg S.C. Nonsteroidal anti-inflammatory drugs and corticosteroids for the management of canine osteoarthritis. Vet Clin North Am Small Anim Pract 27 (1997) 841-862
41. Johnston S.A., Leib M.S., Forrester S.D., et al. The effect of misoprostol on aspirin-induced gastroduodenal lesions in dogs. J Vet Intern Med 9 (1995) 32-38
42. Julou L, Guyonnet JC, Ducrot R, et al. Ketoprofen (19.583 R.P.) (2-(3-benzoylphenyl)-propionic acid). Main pharmacological properties - line of toxicological and pharmacokinetic data. Scand J Rheumatol 1976; Suppl 30: 33-44.
43. Kallings P, Johnston C, Drevemo S. Effects of flunixin on movement and performance of standardbred trotters on the track. Equine Vet J 1999; Suppl 30: 270-3.
44. Karcher L.F., Dill S.G., Anderson W.I., et al. Right dorsal colitis. J Vet Intern Med 4 (1990) 247-253
45. Kargman S., Charleson S., Cartwright M., et al. Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 111 (1996) 445-454
46. Karmeli F., Cohen P., and Rachmilewitz D. Cyclo-oxygenase-2 inhibitors ameliorate the severity of experimental colitis in rats. Eur J Gastroenterol Hepatol 12 (2000) 223-231
47. Kataoka H., Horie Y., Koyama R., et al. Interaction between NSAIDs and steroid in rat stomach: safety of nimesulide as a preferential COX-2 inhibitor in the stomach. Dig Dis Sci 45 (2000) 1366-1375
48. Kauffman G. Aspirin-induced gastric mucosal injury: lessons learned from animal models. Gastroenterology 96 (1989) 606-614
49. Kearney D., Byrne A., Crean P., Cox D., et al. Optimal suppression of thromboxane A(2) formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor. J Am Coll Cardiol 43 (2004) 526-531
50. Kent T.H., Cardelli R.M., and Stamler F.W. Small intestinal ulcers and intestinal flora in rats given indomethacin. Am J Pathol 54 (1969) 237-249
51. Khan K.N., Paulson S., Seibert K., et al. Gastrointestinal and renal safety of a specific COX-2 inhibitor versus NSAIDs in dogs. Vet Pathol 34 (1997) 509
52. Kishimoto Y., Wada K., Nakamoto K., et al. Levels of cyclooxygenase-1 and -2 mRNA expression at various stages of acute gastric injury induced by ischemia-reperfusion in rats. Arch Biochem Biophys 352 (1998) 153-157
53. Khan K.N., Masferrer J.L., Woerner B.M., et al. Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon. Scand J Gastroenterol 36 (2001) 865-869
54. Knapp D.W., Richardson R.C., Bottoms G.D., et al. Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors. Cancer Chemother Pharmacol 29 (1992) 214-218
55. Knapp D.W., Richardson R.C., Chan T.C., et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 8 (1994) 273-278
56. Koki A., Khan N.K., Woerner B.M., et al. Cyclooxygenase-2 in human pathological disease. Adv Exp Med Biol 507 (2002) 177-184
57. Koki A.T., Khan N.K., Woerner B.M., et al. Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis in human epithelial cancers: evidence for potential clinical utility of COX-2 inhibitors in epithelial cancers. Prostaglandins Leukot Essent Fatty Acids 66 (2002) 13-18
58. Kopcha M., and Ahl A.S. Experimental uses of flunixin meglumine and phenylbutazone in food-producing animals. J Am Vet Med Assoc 19 (1989) 445-449
59. Laine L., Sloane R., Ferretti M., et al. A randomized double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production. Gastrointest Endosc 42 (1995) 428-433
60. Laine L., Harper S., Simon T., et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 117 (1999) 776-783
61. Lanas A., Panes J., and Pique J.M. Clinical implications of COX-1 and/or COX-2 inhibition for the distal gastrointestinal tract. Curr Pharm Des 9 (2003) 2253-2266
62. Lanza F.L., Nelson R.S., and Greenberg B.P. Effects of fenbufen, indomethacin, naproxen, and placebo on gastric mucosa of normal volunteers. A comparative endoscopic and photographic evaluation. Am J Med 75 (1983) 75-79
63. Lascelles B.D., Blikslager A.T., Fox S.M., et al. Gastrointestinal tract perforation in dogs treated with a selective cyclooxygenase-2 inhibitor: 29 cases (2002-2003). J Am Vet Med Assoc 227 (2005) 1112-1117
64. Lees P., and Higgins A.J. Clinical pharmacology and therapeutic uses of non-steroidal anti-inflammatory drugs ion the horse. Equine Vet J 17 (1985) 83-96
65. Lesch C.A., Kraus E.R., Sanchez B., et al. Lack of beneficial effect of COX-2 inhibitors in an experimental model of colitis. Methods Find Exp Clin Pharmacol 21 (1999) 99-104
66. Li J.T., Li Z.S., Zhan X.B., et al. Experimental study of the safety of the selective COX-2 inhibitor, celecoxib, for gastic mucosa. Chin J Dig Dis 4 (2003) 53-56
67. Mahmud T., Rafi S.S., Scott D.L., et al. Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation. Arthritis Rheum 39 (1996) 1998-2003
68. Mackay R.J., French T.W., Nguyen H.T., et al. Effects of large doses of phenylbutazone administration to horses. Am J Vet Res 44 (1983) 774-780
69. Masferrer J.L., Zweifel B.S., Manning P.T., et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 91 (1994) 3228-3232
70. Mason J.C. NSAIDs and the oesophagus. Eur J Gastroenterol Hepatol 11 (1999) 369-373
71. Mathews K.A. Nonsteroidal anti-inflammatory analgesics in pain management in dogs and cats. Can Vet J 37 (1996) 539-545
72. Maziasz T.J., Khan K.N.M., Talley J., Gierse J., and Seibert K. The development of drugs that target cycloxygenase-2. In: Harris R.E. (Ed). Cyclooxygenase 2 blockade in cancer prevention and therapy (2003), The Humana Press Inc., Clifton, UK 259-277
73. Mccafferty D.M., Granger D.N., and Wallace J.L. Indomethacin-induced gastric injury and leukocyte adherence in arthritic versus healthy rats. Gastroenterology 109 (1995) 1173-1180
74. Mersereau W.A., and Hinchey E.J. Synergism between acid and gastric contractile activity in the genesis of ulceration and hemorrhage in the phenylbutazone-treated rat. Surgery 90 (1981) 516-522
75. Meschter C.L., Gilbert M., Krook L., et al. The effects of phenylbutazone on the intestinal mucosa of the horse: a morphological, ultrastructural and biochemical study. Equine Vet J 22 (1990) 255-263
76. Meschter C.L., Gilbert M., Krook L., et al. The effects of phenylbutazone on the morphology and prostaglandin concentrations of the pyloric mucosa of the equine stomach. Vet Pathol 27 (1990) 244-253
77. Moore J.N., Garner H.E., Shapland J.E., et al. Prevention of endotoxin-induced arterial hypoxaemia and lactic acidosis with flunixin meglumine in the conscious pony. Equine Vet J 13 (1981) 95-98
78. Murtaugh R.J., Matz M.E., Labato M.A., et al. Use of synthetic prostaglandin E1 (misoprostol) for prevention of aspirin-induced gastroduodenal ulceration in arthritic dogs. J Am Vet Med Assoc 202 (1993) 251-256
79. Rainsford K.D. An analysis of the gastro-intestinal side-effects of non-steroidal anti-inflammatory drugs, with particular reference to comparative studies in man and laboratory species. Rheumatol Int 2 (1982) 1-10
80. Rainsford K.D., Stetsko P.I., Sirko S.P., et al. Gastrointestinal mucosal injury following repeated daily oral administration of conventional formulations of indometacin and other non-steroidal anti-inflammatory drugs to pigs: a model for human gastrointestinal disease. J Pharm Pharmacol 55 (2003) 661-668
81. Reed S. Nonsteroidal anti-inflammatory drug-induced duodenal ulceration and perforation in a mature rottweiler. Can Vet J 43 (2002) 971-972
82. Reimer M.E., Johnston S.A., Leib M.S., et al. The gastroduodenal effects of buffered aspirin, carprofen, and etodolac in healthy dogs. J Vet Intern Med 13 (1999) 472-477
83. Reuter B.K., Davies N.M., and Wallace J.L. Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 112 (1997) 109-117
84. Ricketts A.P., Lundy K.M., and Seibel S.B. Evaluation of selective inhibition of canine cyclooxygenase 1 and 2 by carprofen and other nonsteroidal anti-inflammatory drugs. Am J Vet Res 59 (1998) 1441-1446
85. Roudebush P., and Morse G.E. Naproxen toxicosis in a dog. J Am Vet Med Assoc 179 (1981) 805-806
86. Scheiman J.M. NSAIDs, gastrointestinal injury, and cytoprotection. Gastroenterol Clin North Am 25 (1996) 279-298
87. Scheiman J.M. Gastroduodenal safety of cyclooxygenase-2 inhibitors. Curr Pharm Des 9 (2003) 2197-2206
88. Scherkl R., and Frey H.H. Pharmacokinetics of ibuprofen in the dog. J Vet Pharmacol Ther 10 (1987) 261-265
89. Schmassmann A., Peskar B.M., Stettler C., et al. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. Br J Pharmacol 123 (1998) 795-804
90. Schoenfeld P., Kimmey M.B., Scheiman J., et al. Review article: nonsteroidal anti-inflammatory drug-associated gastrointestinal complications - guidelines for prevention and treatment. Aliment Pharmacol Ther 13 (1999) 1273-1285
91. Shriver D.A., Dove P.A., White C.B., et al. A profile of the gastrointestinal toxicity of aspirin, indomethacin, oxaprozin, phenylbutazone, and fentiazac in arthritic and Lewis normal rats. Toxicol Appl Pharmacol 42 (1977) 75-83
92. Schriver D.A., White C.B., Sandor A., et al. A profile of the rat gastrointestinal toxicity of drugs used to treat inflammatory diseases. Toxicol Appl Pharmacol 32 (1975) 73-83
93. Seibert K., Zhang Y., Leahy K., et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 91 (1994) 12013-12017
94. Seibert K., Zhang Y., Leahy K., et al. Distribution of COX-1 and COX-2 in normal and inflamed tissues. Adv Exp Med Biol 400A (1997) 167-170
95. Sigthorsson G., Jacob M., Wrigglesworth J., et al. Comparison of indomethacin and nimesulide, a selective cyclooxygenase-2 inhibitor, on key pathophysiologic steps in the pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in the rat. Scand J Gastroenterol 33 (1998) 728-735
96. Sigthorsson G., Simpson R.J., Walley M., et al. COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology 122 (2002) 1913-1923
97. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284 (2000) 1247-1255
98. Somasundaram S., Sigthorsson G., Simpson R.J., et al. Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat. Aliment Pharmacol Ther 14 (2000) 639-650
99. Soslow R.A., Dannenberg A.J., Rush D., et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89 (2000) 2637-2645
100. Stanton M.E., and Bright R.M. Gastroduodenal ulceration in dogs. Retrospective study of 43 cases and literature review. J Vet Intern Med 3 (1989) 238-244
101. Takeuchi K., Tanaka A., Hayashi Y., et al. Functional mechanism underlying COX-2 expression following administration of indomethacin in rat stomachs: importance of gastric hypermotility. Dig Dis Sci 49 (2004) 180-187
102. Tanaka A., Araki H., Komoike Y., et al. Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal antiinflammatory drugs. J Physiol Paris 95 (2001) 21-27
103. Tanaka A., Araki H., Hase S., et al. Up-regulation of COX-2 by inhibition of COX-1 in the rat: a key to NSAID-induced gastric injury. Aliment Pharmacol Ther 16 Suppl 2 (2002) 90-101
104. Tanaka A., Hase S., Miyazawa T., et al. Role of cyclooxygenase (COX)-1 and COX-2 inhibition in nonsteroidal anti-inflammatory drug-induced intestinal damage in rats: relation to various pathogenic events. J Pharmacol Exp Ther 303 (2002) 1248-1254
105. Tomlinson J.E., Wilder B.O., Young K.M., et al. Effects of flunixin meglumine or etodolac treatment on mucosal recovery of equine jejunum after ischemia. Am J Vet Res 65 (2004) 761-769
106. Traub J.L., Gallina A.M., Grant B.D., et al. Phenylbutazone toxicosis in the foal. Am J Vet Res 44 (1983) 1410-1418
107. Traub-Dargatz J.L., Bertone J.J., Gould D.H., et al. Chronic flunixin meglumine therapy in foals. Am J Vet Res 49 (1988) 7-12
108. Van Miert A.S., Van Der Wal-Komproe L.E., and Van Duin C.T. Effects of antipyretic agents on fever and ruminal stasis induced by endotoxins in conscious goats. Arch Int Pharmacodyn Ther 225 (1977) 39-50
109. Vonderhaar M.A., and Salisbury S.K. Gastroduodenal ulceration associated with flunixin meglumine administration in three dogs. J Am Vet Med Assoc 203 (1993) 92-95
110. Wallace J.L., Keenan C.M., and Granger D.N. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. Am J Physiol 259 (1990) G462-G467
111. Wallace J.L., Mcknight W., Reuter B.K., et al. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 119 (2000) 706-714
112. Watson A.D., Wilson J.T., Turner D.M., et al. Phenylbutazone-induced blood dyscrasias suspected in three dogs. Vet Rec 107 (1980) 239-241
113. Wight N.J., Gottesdiener K., Garlick N.M., et al. Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production. Gastroenterology 120 (2001) 867-873
114. Zhang L., Lu Y.M., and Dong X.Y. Effects and mechanism of the selective COX-2 inhibitor, celecoxib, on rat colitis induced by trinitrobenzene sulfonic acid. Chin J Dig Dis 5 (2004) 110-114